Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
3.800
+0.080 (2.15%)
At close: Oct 24, 2025, 4:00 PM EDT
3.780
-0.020 (-0.53%)
After-hours: Oct 24, 2025, 5:11 PM EDT
Veru Inc. Revenue
Veru Inc. had revenue of $16.89M in the twelve months ending June 30, 2025, up 337.24% year-over-year. In the fiscal year ending September 30, 2024, Veru Inc. had annual revenue of $16.89M with 3.62% growth.
Revenue (ttm)
$16.89M
Revenue Growth
+337.24%
P/S Ratio
3.30
Revenue / Employee
$80,412
Employees
210
Market Cap
55.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 16.89M | 589.46K | 3.62% |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VERU News
- 4 weeks ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire
- 2 months ago - Veru Inc. (VERU) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - GlobeNewsWire
- 2 months ago - Veru Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - Veru to Participate in the 2025 BTIG Virtual Biotech Conference - GlobeNewsWire
- 4 months ago - Veru to Participate in the Virtual BTIG Obesity Health Forum - GlobeNewsWire
- 5 months ago - Veru's Enobosarm Shows Muscle In Wegovy Combo Trial - Benzinga